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The occurrence of resistance to chemotherapeutic drugs contributes to the incurability of tumours and is a major probhm for successful cancer treatment. In view of the major side-effects of chemotherapy, treatment with drugs to which the tumour cells display an intinsic or acquired resistance should be avoided. Assays to predict the esponsiveness to chemotherapeutic drugs are therefore of great interest for successfl chemotherapeutic treatment of tumours. Drugs, such as doxorubicin, etoposide and 4'-(9-acridinylamino) methane-sulphon-m-anisidide (m-AMSA), which inhibit the enzyme topoisomerase H (topo II) are widely used as antitumour agents. Currently, two main categories of reistance mechanisms are known to interfere with this kind of drug. The first category concerns a s ulting in a reduced drug concentration at the target site and will give a multidrug resistance (MDR) phenotype. Two drug efflux pumps have been identifed that can cause a reduced drug concentration at the target site, P-glycoprotein (Gros et al., 1986; Ueda et al., 1986 ) and the mulfidrug resistanceassocated proten (MRP) (Grant et al., 1994; Zaman et al., 1994) . The second category of resistance, on which we will focus in this study, involves alterations affecting the drug target, the enzyme topo H.
Topo H is an ubiquitous enzyme that can alter the topological state of DNA and untangle intertwined DNA helices (reviwed in Chen and Liu, 1994; Wang, 1985) . As such, it plays an essential role in several cellular events such as replication (DiNardo et al., 1984) , chromatin condensation (Uemura et al., 1987) and sister chromatid segregation (DiNardo et al., 1984; Uemura et al., 1987) . Topo H is also one of the major components of the nuclear matrix and the chromosomal scaffold (Earnshaw et al., 1985; Taagepera et al., 1993) . Topo H cleaves double-stranded DNA through the cleavable complex, followed by hydrolysis of ATP and reseaing of the double-stranded DNA (Chen and liu, 1994) . Topo H-inhibiting drugs stabilise the cleavable complex, reulting in both singl-and double-strand DNA breaks (Nelson et al., 1984; Glisson et al., 1986) , which can lead to cell death.
Two topo H isoforms, topo HaE (170kDa) and topo II0 (180 kDa), exist in animal cells. Although both enzymes are closely related (72% identical amino acid residues; Jenkins et al., 1992), they differ in important biochemical and biophysical prop . It has been reported for some human cell lins that the topo HaE form is predominantly located in the nuceoplasm (Zini et al., 1994) , whereas the topo Hp form is mainly located in the nucleolus (Boege et al., 1993; Coutts et al., 1993; 7ini et al., 1994) . In Chinese hamster ovary cells both isoforms are detected in the nucleoplasn and in the nucleolus (Petrov et al., 1993) . Topo HaE expression is low in quiescent cells, increases in S-phase and is maximal in G2-M phaw, whereas topo HP expression is constant throughout the cell cyce (Woessner et al., 1991; Prosperi et al., 1992 (Eder et al., 1993; Gudkov et al., 1993; Nitiss et al., 1993) . As different sensitivities of the topo HaE and 1 isoforms to topo H-inhibiting drugs have been reported (Drake et al., 1989) , the relative amount of each isozyme may also be a determinant of resistance to anti-tumour drugs.
In cell lines selcted for resistance to topo H-inhibiting drugs, the topo Ha enzyme levels may be reduced (De Jong et al., 1990 , Matsuo et al., 1990 Cole et al., 1991 (Harker et al., 1991) . Posttranslational modifications of topo Ila also appear to affect the catalytic activity and sensitivity to drugs in resistant cell lines (Takano et al., 1991; Boege et al., 1993; Ganapathi et al., 1993) .
We have previously shown that in doxorubicin-selected variants of the human SW-1573 non-small cell lung cancer cell line drug resistance is due to two alterations: a decreased drug accumulation and a reduced topo IIo mRNA level (Eijdems et al., 1992) . The drug accumulation defect and the alteration in topo IIa mRNA are not genetically linked and could be separated by somatic cell fusion (Eijdems et al., 1992 (Broxterman et al., 1989; Keizer et al., 1989; Baas et al., 1990 
RNAse protection assay
The RNAse protection assay was performed as described previously (Baas et al., 1990) . Ten micrograms of total cytoplasmic RNA from each cell line was used or 10 jig of E. coli tRNA (Boehringer Mannheim, Germany) as a negative control. The protected probes were visualised by electrophoresis through a denaturing 6% acrylamide gel containing 8 M urea, followed by autoradiography. The topo IIa probe was a 174 nt topo Ila cDNA fragment (nucleotide positions 1343 -1517 Tsai-Plugfelder et al., 1988) . In all experiments a probe for y-actin (Enoch et al., 1986) was included as internal control.
Southern hybridisations
To prepare Southern blots, genomic DNA was isolated as previously described (Miller et al., 1988) or cells were embedded in low melting point agarose plugs (Gibco BRL, Gaithersburg, MD, USA), lysed and deproteinised as described previously (Schwartz and Cantor, 1984) . After digestion the generated fragments were separated on a 1% agarose gel in a regular electric field or in a contour-clamped Preparation of nuclear enzyme extracts Nuclei were isolated as described previously (Pommier et al., 1986) . Briefly, log-phase cells (2.5 x 10 cells ml-') were pelleted by centrifugation at 150 g for 10 min and washed twice with ice-cold PBS. The cell pellets were resuspended in 1 ml of nucleus buffer (150 mM sodium chloride, 1 mm potassium dihydrogen phosphate. 5 mM magnesium chloride, 1 mM EGTA, 2 mM dithiotreitol and 1 mM PMSF, pH 6.4) at 4°C and then mixed with an additional 9 ml of nucleus buffer containing 0.3% Triton X-100. The cell suspension was mixed gently by rotation for 10 min at 4°C followed by centrifugation at 150 g for 10 min at 4°C. Figure 3 for doxorubicin-selected cell lines 25.10 and 30.3M, and for vincristine-selected cell line 20V2. For comparison, the curve for the parental cell line Slou is indicated in each graph. In this assay m-AMSAresistant cell line 25.10, which had wild-type topo lIcx and topo 10 levels, also showed a clear reduction in the number of m-AMSA-induced DNA breaks. To express the number of m-AMSA-induced DNA breaks quantitatively, the mean weighted ratio across the curve for each of the resistant cell lines over the curve for the parental cell line S lou was determined (Table I) . These ratios, representing the relative DNA break fractions, show a clear correlation with m-AMSA resistance (correlation coefficient = 0.96).
Comparison of m-AMSA-and VP16-213-induced DNA breaks in the non-Pgp MDR cell line IR50b
The results in Table I indicate that m-AMSA is not affected by the drug efflux mechanism underlying MDR in the SW-1573 cells, in agreement with results obtained in a previous study (Eijdems et al., 1992 (Figure 3 and Table I ). A larger amount of nuclear extract proteins was used for cell line 25.10 than for
Slou to obtain more or less similar decatenation activity (compare lanes 1 in Figure 4 ). The method we used in this paper allows the measurement of DNA damage after exposure of living cells to topo IIinhibiting drugs as an end point of topo II activity, and circumvents some of the difficulties described above. We tested this assay on a series of in vitro-selected drug-resistant sublines of the human SW-1573 non-small cell lung cancer cell line. This panel of cell lines might represent the in vivo situation, since a low drug concentration was used for selection. The relative number of m-AMSA-induced DNA breaks measured in these lines showed a strong correlation with their m-AMSA sensitivity (r = 0.96). We conclude that the amount of m-AMSA-induced DNA damage is representative of the topo II activity in the different SW-1573 cell lines.
Our results emphasise the need for an assay to measure drug-induced DNA breaks as a parameter for topo II activity instead of topo II expression levels. Three of the five doxorubicin-selected cell lines showed a reduced topo IIx protein level, corresponding to reduced topo IIa mRNA levels. In these three cell lines a reduced number of m-AMSA-induced DNA breaks was found, reflecting reduced topo II activity. In the doxorubicin-selected cell line 25.10, however, a reduced topo II activity was detected in the absence of reduced topo IIa and topo IIP RNA and protein levels. This altered topo II activity was missed with the quantitative assays.
In the cell panel analysed here topo IIa mRNA levels did not correlate with DNA break fractions (r = 0.63) or m-AMSA resistance (r = 0.53). Omission of the data for cell line 25.10, however, resulted in a good correlation of topo IIa mRNA levels with both parameters (r = 0.94 and r = 0.98 respectively). In agreement with this, omission of the data for 25.10 did not affect the strong correlation between DNA breaks and m-AMSA resistance (r = 0.98). We conclude from these calculations that the reduced topo II activity in the m-AMSA-resistant cell lines 30.12, 40.3 and iRSOb is only determined by the reduction in topo Iot mRNA.
The DNA break assay used here combines the DNA unwinding assays, on which alkaline elution is based, with the immunochemical detection of single-stranded DNA. This assay has several advantages over other topo II assays. First, it is very sensitive: a total of about 2 x I04 cells suffices. Second, the method is rapid and simple. There is no need for the extraction of nuclear enzymes, avoiding enzyme losses. Third, the method does not require cell growth in vitro. Fourth, the effect of the drug is measured in its physiological environment in whole cells. Thus, the contribution of mechanisms affecting drug uptake, extrusion and drug concentration is taken into account as well. A disadvantage of the assay is that the cell sample must survive a 1 h incubation at 37°C' without substantial cell disintegration. This may be difficult to achieve with samples from solid tumours.
The advantage that other resistance mechanisms are taken into account as well is illustrated by our results with cell line IRSOb when VP16-213 instead of m-AMSA was used to induce DNA breaks. In somatic cell fusions a reduction in drug accumulation was transferred to drug-sensitive cells, whereas resistance to m-AMSA and an altered topo Ilc mRNA level were not (Eijdems et al., 1992) . Thus, m-AMSA cytotoxicity might solely reflect the activity status of topo II, in agreement with the results presented in this study (Table  I) . Cytotoxicity to other topo II drugs such as VP16-213, in contrast, was also linked to reduced drug accumulation and (Ferguson et al., 1988; De Jong et al., 1990; Cole et al.. 1991 : Friche et al.. 1991 Schneider et al.. 1994) , this might be a general phenomenon.
In conclusion, the immunochemical assay used here measures DNA damage as an end point of topo II activity and allows predictive testing of tumour cell lines for sensitivity to drugs that interact with topo II. We showed that, at very low drug concentrations, quantitative and qualitative topo II alterations can accompany a MDR mechanism. In view of this complexity, immunochemical assays as described here might be more useful for clinical applications than quantitative topo II assays based on measurements of RNA or protein levels.
